Effect of Anapsos in a murine model of experimental trichomoniasis.
Immunomodulator effect of Anapsos (Polypodium leukotomas extract) in NMRI (US Naval Medical Research Institute) outbred mice infected by the intraperitoneal route with 10(7) Trichomonas vaginalis has been tested. Gross histopathologic changes in abdominal organs and mortality rate, as a consequence of the pathogenicity of the protozoa and the immune response of the host, were evaluated. Among the different treatment regimes assayed, Anapsos at doses of 20 mg/Kg/day administered for 10 days before infection decreases the parasite pathogenicity index (PI) in the treated animals when compared to those of the untreated control group. The immunosuppressor treatments with azathioprine (100 mg/Kg/day x 1), cyclophosphamide (100 mg/Kg/day x 1), and FK-506 (10 mg/Kg/day x 10) significantly decreased the PI, while an immunostimulant treatment with glycophosphopeptical (13 mg/Kg/day x 10) increased it. These assays have shown the usefulness of the murine model of experimental trichomoniasis for the study of immunomodulator activity of natural or synthetic drugs.
Nogal-Ruiz
J J
JJ
Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense, Pza. Ramón y Cajal s/n, 28040 Madrid, Spain.
Gómez-Barrio
A
A
Escario
J A
JA
Martínez-Fernández
A R
AR
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001379:Azathioprine / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D004305:Dose-Response Relationship, Drug; D005260:Female; D006027:Glycosides / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D051379:Mice; D010936:Plant Extracts / Q000494:pharmacology; D032494:Polypodium / Q000737:chemistry; D011897:Random Allocation; D016559:Tacrolimus / Q000494:pharmacology; D014245:Trichomonas Infections / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D014247:Trichomonas Vaginitis / Q000276:immunology / Q000469:parasitology / Q000473:pathology; D014246:Trichomonas vaginalis / Q000254:growth & development / Q000276:immunology / Q000472:pathogenicity*
D000276:Adjuvants, Immunologic; D006027:Glycosides; D007166:Immunosuppressive Agents; D010936:Plant Extracts; C006870:anapsos; D003520:Cyclophosphamide; D001379:Azathioprine; D016559:Tacrolimus